MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
MAIA Biotechnology has received regulatory approval to start patient screening in Spain and Portugal for its Phase 3 THIO-104 trial targeting non-small cell lung cancer (NSCLC). This expansion broadens access to the investigational therapy, ateganosine, in important European markets with significant NSCLC incidence. The company aims to enroll 100 p…